Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Candesartan Recombinant Mouse Monoclonal Antibody (6G10)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 1
Candesartan Antibody (MA566600) in SDS-PAGE
SDS-PAGE characterization of Candesartan under reducing conditions. Lane M: Protein marker (kDa); Lane CDT: Purified Candesartan Recombinant Monoclonal (Product # MA566600). Candesartan showing heavy chain (~50 kDa) and light chain (~25 kDa). Gels were stained with Coomassie Brilliant Blue R-671.
产品信息
MA566600
产品规格
种属反应
Chemical
宿主/亚型
Mouse
/ IgG
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
克隆号
6G10
抗原
Conjugate of CDT hapten and KLH.
偶联物
形式
Liquid
浓度
5.9 mg/mL
纯化类型
Protein G
保存液
PBS
内含物
0.09% sodium azide
保存条件
-20°C
运输条件
Ambient (domestic); Wet ice (international)
靶标信息
Candesartan is an angiotensin II receptor antagonist that functions by binding to the AT1 receptor, thereby preventing angiotensin II from exerting its vasoconstrictive and aldosterone-secreting effects. It is commonly used in the treatment of hypertension and is available as a prodrug, candesartan cilexetil, which is metabolized into its active form in the body. The pharmacokinetic parameters such as C max, AUC 0-t, and AUC 0-infinity have been studied to ensure bioequivalence in various formulations. Candesartan's dosage can be individualized, typically ranging from 4 to 32 mg daily. The development of candesartan biosimilars involves ensuring these pharmacokinetic parameters fall within the acceptable range to maintain efficacy and safety. This drug is part of a broader category of angiotensin-receptor blockers (ARBs) and has been the subject of systematic approaches to prodrug development to enhance its therapeutic profile.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
